Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CytoDyn's Enterprise Value is $340.04 Mil.
CytoDyn's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 was $-35.85 Mil. Therefore, CytoDyn's EV-to-EBIT ratio for today is -9.49.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, CytoDyn's Enterprise Value is $340.04 Mil.
CytoDyn's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 was $-35.83 Mil. Therefore, CytoDyn's EV-to-EBITDA ratio for today is -9.49.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, CytoDyn's Enterprise Value is $340.04 Mil.
CytoDyn's Revenue for the trailing twelve months (TTM) ended in Feb. 2026 was $0.00 Mil. Therefore, CytoDyn's EV-to-Revenue ratio for today is .
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, CytoDyn's Enterprise Value is $340.04 Mil.
CytoDyn's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 was $-17.98 Mil. Therefore, CytoDyn's EV-to-FCF ratio for today is -18.91.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
CytoDyn (OTCPK:CYDY) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
CytoDyn's current Enterprise Value is $340.04 Mil.
CytoDyn's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.85 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
CytoDyn's current Enterprise Value is $340.04 Mil.
CytoDyn's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.83 Mil.
CytoDyn's current Enterprise Value is $340.04 Mil.
CytoDyn's Revenue for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
CytoDyn's current Enterprise Value is $340.04 Mil.
CytoDyn's Cash Flow from Operations for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.98 Mil.
CytoDyn's current Enterprise Value is $340.04 Mil.
CytoDyn's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoDyn Enterprise Value Related Terms
CytoDyn Enterprise Value Historical Data
* Premium members only.
The historical data trend for CytoDyn's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CYDY vs VSTM, IRD, PALI: Enterprise Value Comparison
For the Biotechnology subindustry, CytoDyn's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoDyn Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoDyn's Enterprise Value distribution charts can be found below:
* The bar in red indicates where CytoDyn's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
CytoDyn's Enterprise Value for the fiscal year that ended in May. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoDyn (CYDY) has a Enterprise Value of $340.04 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on CytoDyn and its competitors.
Is CytoDyn's Enterprise Value too high?
CytoDyn's current Enterprise Value is $340.04 Mil. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Enterprise Value compare to VSTM and IRD?
CytoDyn's Enterprise Value of $340.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on CytoDyn and its competitors. CytoDyn's current Enterprise Value is $340.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (CYDY) has a current Enterprise Value of $340.04 Mil. The current Enterprise Value is $340.04 Mil. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For CytoDyn (CYDY), the current Enterprise Value is $340.04 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score
Get the complete analysis for CYDY
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CYDY has been successfully added to your 
